By Julia Karow

As other DNA sequencing firms continue developing platforms that they say will deliver long reads at low cost, 454 Life Sciences plans to make additional upgrades to its Genome Sequencer FLX platform, aiming to take market share from Sanger sequencing.

Over the next few months, the company, which is part of Roche, plans to roll out a variety of improvements for the GS FLX, including longer reads, a new library protocol, amplicon sequencing for the Titanium platform, and new assembly software.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.